Retatrutide 20mg

Retatrutide engages three structurally related class B G-protein coupled receptors. At the GLP-1 receptor, activation elevates intracellular cyclic AMP in pancreatic beta cells and potentiates glucose-stimulated insulin secretion, while engagement in hypothalamic and brainstem nuclei modulates POMC and AgRP neuronal activity to reduce caloric intake in preclinical feeding studies. At the GIP receptor, signaling contributes additional insulinotropic effects under hyperglycemic conditions and has been implicated in adipose tissue lipid handling.

Activation of the glucagon receptor, predominantly expressed on hepatocytes, increases hepatic cyclic AMP and mobilizes glycogen and lipid stores. In isolation, glucagon agonism elevates glucose output, but when combined with incretin-receptor engagement in a single molecule, investigators have observed that net glycemic effects remain favorable while energy expenditure increases. Preclinical work has reported elevated oxygen consumption and reductions in hepatic triglyceride content in rodent models, consistent with a thermogenic and lipid-mobilizing contribution from the glucagon component. The relative potencies at the three receptors were tuned during medicinal chemistry to balance these opposing actions.